FORT LEE, N.J., Oct. 21 /PRNewswire/ -- Metaphore Pharmaceuticals, Inc., an emerging pharmaceutical company developing drugs for the treatment of pain, autoimmune disorders and inflammation, today announced that Dr. Robert Medve, Metaphore's Senior Vice President, Development, will discuss the topic of pain management at CBI's Clinical Applications of Pain Therapeutics Conference on October 29, 2004, at 9:45 a.m. (PT). The conference is being held from October 28-29, 2004 at the Sheraton Suites Hotel in San Diego, California.
Dr. Medve's presentation, entitled "Strategies in Post-Surgical Pain Management to Alleviate Pain with Minimal Side Effects," will highlight:
* Current limitations of post-operative pain management
* Importance of managing post-operative pain
* Drug development issues for new indications
* Potential for Metaphore's lead compound, M40403, to change the
therapeutic index of opioids
Metaphore is developing drugs, known as SOD mimetics, for the management of pain in several indications including post-surgical pain. The company's novel non-narcotic medication has demonstrated the ability to selectively enhance the pain-relieving effects of opioids while reducing the unwanted side effects associated with both chronic and acute opioid use. Furthermore, these compounds also may prevent opioid tolerance and restore opioid efficacy once tolerance develops. In human studies, adding M40403 to morphine has made the opioid more effective and more predictable by virtually every measure of analgesic efficacy, including faster onset, longer duration, greater peak effect, and greater overall effect.
About M40403 and SOD Mimetics
Metaphore's lead compound, M40403iv, is a synthetic version of a naturally occurring enzyme produced by the body known as superoxide dismutase (SOD). SOD functions in the body to neutralize free radicals, thereby reducing inflammation, preventing tissue injury and reducing pain. These free radicals, called superoxides, are overproduced in the presence of cell or tissue injury, inflammation and many disease processes. Elevated levels of superoxides can overwhelm the body's natural production of SODs, resulting in a continuing cycle of cell injury, inflammation, and pain. Metaphore has developed SOD mimetics (SODm), which are synthetic compounds that mimic the actions of SODs and supplement the body's natural process of reducing inflammation, limiting cellular damage and relieving pain.
In addition, SODm has the ability to substantially contribute to the pain relieving benefits associated with opioids. In Phase II Clinical Trials, M40403 markedly improved the pain relief produced by opioids while making them more effective and more predictable. In independent tests by the National Institute on Drug Abuse, M40403 was found to have no addictive properties or abuse liability.
More about the Company
Metaphore Pharmaceuticals, Inc. is a privately held, emerging pharmaceutical company which discovers, develops and will market drugs that prevent and treat pain, autoimmune disorders and inflammation. The company leverages its expertise in chemistry and biology to discover and develop small molecule compounds that mimic the activity of human enzymes. Metaphore's lead compounds mimic the function of superoxide dismutase (SOD), a beneficial enzyme that serves an important protective role in the body by removing superoxide, a toxic free radical that can damage cells and tissues. Superoxide anions are implicated in a variety of diseases associated with pain and inflammation.
Metaphore has a global, multilayered intellectual property estate covering its broad class of compounds including composition of matter and use patents. This IP estate includes 70 issued and 63 pending worldwide patents.
Product candidates in U.S. clinical testing have broad therapeutic potential across a variety of diseases. Metaphore currently focuses its clinical development efforts in pain, rheumatoid arthritis and inflammatory disorders. These markets are significant in terms of scope and size. The company maintains offices in Fort Lee, New Jersey and St. Louis, Missouri. For more information on Metaphore, please visit the Web site at: http://www.metaphore.com/ .
This press release contains forward-looking statements based on information available to Metaphore as of the date hereof. In some cases, you can identify these forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other comparable terminology. Metaphore's actual results could differ materially from the results stated or implied by such forward-looking statements due to a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, general economic and business conditions, changes in governmental laws and regulations relating to the development and commercialization of pharmaceutical products, and competition in our industry. In addition, we are developing several products for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Metaphore disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Metaphore Pharmaceuticals, Inc.
CONTACT: Alan W. Dunton, M.D., President and Chief Executive Officer,+1-201-947-7707, firstname.lastname@example.org, or Sara E. K. Cooper, Director ofCorporate Communications, +1-201-947-7707, email@example.com, both ofMetaphore Pharmaceuticals; or Scott M. Solomon, Vice President of SharonMerrill Associates, Inc., +1-617-542-5300, ssolomon@InvestorRelations.com, forMetaphore Pharmaceuticals, Inc.; or Matt Dallas, Vice President of FinancialDynamics, +1-212-850-5627, firstname.lastname@example.org, for Metaphore Pharmaceuticals,Inc.